Abstract
People with multiple sclerosis (MS), a chronic neurologic disease, typically undergo brain magnetic resonance imaging (MRI) to assess for new disease activity or to evaluate response to disease-modifying therapy. The required frequency of these imaging studies has not yet been determined, and clinicians rely on expert panel recommendations or intuition to select the interval length for their patients. These former recommendations are often broad and lack the incorporation of individualized information (i.e., age, presence of recent disease activity, type of disease modifying therapy) into the synthesis of their assessment. We developed an algorithm that can predict new disease activity (i.e., lesions) on the next MRI scan. Multiple data sources from the electronic health records of 1045 patients were used to train and test the algorithm which resulted in an accurate solution with an area under the curve (AUC) of 0.8 that minimizes missed lesions while accurately identifying two-thirds of patients as not having a new lesion in subsequent MRI. We believe that this algorithm can be developed into a clinical decision support tool as input into a clinician-patient assessment of the appropriate interval length between MRIs for a specific patient.
Competing Interest Statement
Dr. Sotirchos has received personal compensation for serving as a Consultant for Ad Scientiam. Dr. Sotirchos has received personal compensation for serving on a Scientific Advisory or Data Safety Monitoring board for Viela Bio. Dr. Sotirchos has received personal compensation for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Sotirchos has received personal compensation for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Sotirchos has received personal compensation for serving as an Ad Hoc Reviewer with National Institutes of Health. Dr. Mowry has received royalty payments from UpToDate. Dr. Mowry has received research support from Biogen and Genentech, editorial royalties from UpToDate, and consulting fees from BeCareLink, LLC. Dr. Peter Calabresi has received personal compensation as a consultant for Novartis. Dr. Peter Calabresi has received personal compensation for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Calabresi has received personal compensation for serving on a Scientific Advisory or Data Safety Monitoring board for Idorsia. An immediate family member of Dr. Calabresi has received personal compensation for serving on a Scientific Advisory or Data Safety Monitoring board for MyMD. Dr. Calabresi has received personal compensation for serving as an Editor, Associate Editor, or Editorial Advisory Board Member and as a Grant reviewer for Myelin Repair Foundation. Dr. Calabresi has received publishing royalties from a publication relating to health care. Dr. Calabresi has received personal compensation for serving as a Study Section Member with NIH. Dr. Calabresi has received personal compensation for serving as a Speaker for CME with NYAS. Dr. Calabresi has received personal compensation for serving as a Speaker with Academic CME. Dr. Calabresi has received personal compensation for consulting with Lilly and Project Efflux. The institution of Dr. Calabresi has received research support from Genentech. The institution of Dr. Sotirchos has received research support from National Institutes of Health. The institution of Dr. Sotirchos has received research support from National Multiple Sclerosis Society. The institution of Dr. Sotirchos has received research support from Sumaira Foundation. The institution of Dr. Sotirchos has received research support from Genentech. Dr. Ferryman is a Member of the Digital Ethics Advisory Panel for Merck KGaA (Merck Germany) and a Member of the Institutional Review Board for the All of Us Research Program, National Institutes of Health.
Funding Statement
This study was partially funded by JHU internal research investments as well as NIH K23NS117883 (ESS), NMSS RG-1904-33834 (ESS), and NMSS Sylvia Lawry Fellowship (KGR)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of Johns Hopkins Medicine gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
We have updated the manuscript to include updated figures and text to clarify our approach and resulting analysis.
Data Availability
All data produced in the present study are available upon reasonable request to the authors, subject to IRB and data use agreements.
